Review
Immunology
Nicola Luigi Bragazzi, Charlie Bridgewood, Abdulla Watad, Giovanni Damiani, Dennis McGonagle
Summary: This review examines the sex-specific differences related to psoriatic arthritis (PsA) and discusses their implications for clinical research and epidemiology.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Rheumatology
Laura C. Coates, Irene E. van der Horst-Bruinsma, Ennio Lubrano, Steph Beaver, Emma Drane, Baran Ufuktepe, Alexis R. Ogdie
Summary: This systematic review aims to gather evidence on sex-specific differences in clinical characteristics, disease activity, and patient-reported outcomes in Psoriatic Arthritis (PsA). The review indicates that women have higher rates of peripheral disease, including tender joint counts, while men have more severe axial disease and greater skin disease burden. Women also have poorer scores in PROs, including pain and fatigue, and show worse responses to treatment measured by outcomes such as ACR responses and minimal disease activity.
JOURNAL OF RHEUMATOLOGY
(2023)
Review
Rheumatology
Sanjana Tarannum, Ying-Ying Leung, Sindhu R. Johnson, Jessica Widdifield, Vibeke Strand, Paula Rochon, Lihi Eder
Summary: This narrative review focuses on the influence of sex and gender on psoriatic arthritis, covering disease progression and outcomes, underlying mechanisms, and response to therapies. It also discusses the disparities between male and female patients in terms of treatment response and differences in pathophysiological mechanisms including genetics, immune, and hormonal mechanisms. Furthermore, it outlines the association of psoriatic arthritis with fertility and pregnancy outcomes.
NATURE REVIEWS RHEUMATOLOGY
(2022)
Article
Rheumatology
E. Passia, M. Vis, L. C. Coates, A. Soni, I Tchetverikov, A. H. Gerards, M. R. Kok, P. A. J. M. Vos, L. Korswagen, F. Fodili, Y. P. M. Goekoop-Ruiterman, J. van der Kaap, M. van Oosterhout, J. J. Luime
Summary: Prevalence of psoriatic arthritis (PsA) is equal in men and women, but women experience a higher burden of disease, including higher pain levels and lower functional capacity, and are more frequently affected by polyarthritis.
ARTHRITIS RESEARCH & THERAPY
(2022)
Article
Rheumatology
Victoria Furer, Jonathan Wollman, David Levartovsky, Valerie Aloush, Ofir Elalouf, Hagit Sarbagil-Maman, Liran Mendel, Sara Borok, Daphna Paran, Ori Elkayam, Ari Polachek
Summary: This study found that male patients with psoriatic arthritis (PsA) had more severe enthesitis based on ultrasound evaluation. These sex-based differences in enthesitis were not reflected in disease activity scores derived from clinical assessment.
JOURNAL OF RHEUMATOLOGY
(2023)
Review
Medicine, General & Internal
Roberta Naddei, Ana Rebollo-Gimenez, Marco Burrone, Valentina Natoli, Silvia Rosina, Alessandro Consolaro, Angelo Ravelli
Summary: Juvenile psoriatic arthritis (JPsA) is a controversial subset of juvenile idiopathic arthritis (JIA), accounting for 1-7% of cases. There has been debate about whether JPsA should be classified as a distinct category within JIA. Studies have shown that children with JPsA can be divided into two subgroups based on their clinical features and genetic determinants. The ongoing discussion has prompted the revision of the current classification of JPsA.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Rheumatology
Katinka Albrecht, Anne Constanze Regierer, Anja Strangfeld, Ursula Marschall, Johanna Callhoff
Summary: This study examined the use of multiple medications in patients with psoriatic arthritis (PsA) and found that the frequency of medication use was significantly higher compared to the control group, particularly for musculoskeletal, immunomodulatory, cardiovascular, alimentary tract/metabolic, and nervous system drugs. Polypharmacy was common in PsA and increased with age and comorbidity, affecting both men and women equally.
Review
Immunology
Theo Wirth, Nathalie Balandraud, Laurent Boyer, Pierre Lafforgue, Thao Pham
Summary: PsA diagnosis and treatment is often delayed, resulting in joint damage and disability. Research has identified potential biomarkers to improve PsA diagnosis and prognosis, but further studies are needed to evaluate their performance.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Rheumatology
Irina Gessl, Claudia A. Hana, Thomas Deimel, Martina Durechova, Miriam Hucke, Victoria Konzett, Mihaela Popescu, Paul Studenic, Gabriela Supp, Michael Zauner, Josef S. Smolen, Daniel Aletaha, Peter Mandl
Summary: The study aimed to assess the predictive value of tenderness in non-swollen joints for subsequent radiographic progression in rheumatoid arthritis (RA) and psoriatic arthritis (PsA), taking into consideration other potential risk factors. Clinical and sonographic examination of hand joints were performed on patients with RA and PsA. The results showed that tenderness in non-swollen joints was associated with radiographic progression in RA, while the impact was weaker in PsA. Other risk factors such as sonographic signs for synovitis and baseline radiographic damage also had an effect on subsequent structural damage in both diseases.
ANNALS OF THE RHEUMATIC DISEASES
(2023)
Review
Genetics & Heredity
Alberto Floris, Mattia Congia, Elisabetta Chessa, Maria Maddalena Angioni, Matteo Piga, Alberto Cauli
Summary: Specific and high-quality evidence on the efficacy of current targeted therapies for axial disease in psoriatic arthritis (axPsA) is lacking. More studies specifically designed for axPsA and based on validated definition and outcome measures are urgently needed to provide reliable evidence.
FRONTIERS IN GENETICS
(2021)
Article
Medicine, General & Internal
Fan Yang, Chaofan Lu, Huilan Liu, Lei Dou, Yanhong Wang, Hongbin Li, Xinwang Duan, Lijun Wu, Yongfu Wang, Xiuying Zhang, Jian Xu, Jinmei Su, Dong Xu, Jiuliang Zhao, Qingjun Wu, Mengtao Li, Xiaomei Leng, Xiaofeng Zeng
Summary: Enthesitis is common in Chinese patients with PsA, and it is important to evaluate both peripheral and axial sites. Compared with other cohorts, Chinese patients with enthesitis tend to be younger, have a lower body mass index, a higher rate of positive HLA-B27, more frequent dactylitis, and a higher proportion of csDMARDs use.
CHINESE MEDICAL JOURNAL
(2023)
Review
Pharmacology & Pharmacy
Hannah A. Blair
Summary: Secukinumab is an effective treatment for PsA across all key domains, with low rates of adverse effects and sustained long-term efficacy. It is a useful alternative to TNFi and other bDMARDs for adult patients with active PsA.
Review
Dermatology
Alice B. Gottlieb, Joseph F. Merola
Summary: Psoriasis is a chronic inflammatory disorder that can lead to psoriatic arthritis, a heterogeneous musculoskeletal disease causing joint damage. Early detection and intervention by dermatologists is crucial in preventing permanent joint damage from psoriatic arthritis, which often manifests after skin symptoms.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
(2021)
Article
Medicine, General & Internal
Oliver FitzGerald, Alexis Ogdie, Vinod Chandran, Laura C. Coates, Arthur Kavanaugh, William Tillett, Ying Ying Leung, Maarten deWit, Jose U. Scher, Philip J. Mease
Summary: Psoriatic arthritis (PsA) is a complex inflammatory disease related to psoriasis, presenting challenges in diagnosis and treatment. There are no diagnostic criteria or tests available, and disease heterogeneity may be explained by differences in genotype. New targeted therapies have shown promise in improving outcomes for PsA patients.
NATURE REVIEWS DISEASE PRIMERS
(2021)
Review
Immunology
Eric Toussirot, Irene Gallais-Serezal, Francois Aubin
Summary: Psoriasis and psoriatic arthritis are immune-mediated diseases that affect the skin, joints or both. They involve complex pathophysiological mechanisms and increased inflammation. These conditions are also associated with a higher risk of cardiometabolic diseases, which are linked to systemic inflammation and can impact disease severity and treatment outcomes.
FRONTIERS IN IMMUNOLOGY
(2022)
Letter
Rheumatology
Pedro M. Machado, Martin Schaefer, Anja Strangfeld, Laure Gossec, Milena Gianfrancesco, Saskia Lawson-Tovey, Elsa F. Mateus, Loreto Carmona, Kimme L. Hyrich, Philip C. Robinson, Jinoos Yazdany
ANNALS OF THE RHEUMATIC DISEASES
(2023)
Letter
Rheumatology
Martin Schaefer, Anja Strangfeld, Kimme L. Hyrich, Loreto Carmona, Milena Gianfrancesco, Saskia Lawson-Tovey, Elsa F. Mateus, Laure Gossec, Philip C. Robinson, Jinoos Yazdany, Pedro M. Machado
ANNALS OF THE RHEUMATIC DISEASES
(2023)
Letter
Rheumatology
Kimme L. Hyrich, Martin Schaefer, Anja Strangfeld, Loreto Carmona, Laure Gossec, Elsa F. Mateus, Saskia Lawson-Tovey, Milena Gianfrancesco, Philip C. Robinson, Jinoos Yazdany, Pedro M. Machado
ANNALS OF THE RHEUMATIC DISEASES
(2023)
Letter
Rheumatology
Ricardo J. O. Ferreira, Paco M. J. Welsing, Johannes W. G. Jacobs, Laure Gossec, Mwidimi Ndosi, Pedro M. Machado, Desiree van der Heijde, Jose A. P. Da Silva
ANNALS OF THE RHEUMATIC DISEASES
(2023)
Letter
Rheumatology
Telma Thrastardottir, Elana Meer, Arna Hauksdottir, Bjorn Gudbjornsson, Sigurdur Yngvi Kristinsson, Alexis Ogdie, Thorvardur Jon Love
Article
Rheumatology
Patricia Katz, Sofia Pedro, Kaleb Michaud
Summary: This study aims to explore sleep problems in patients with rheumatoid arthritis (RA), and found a high prevalence of obstructive sleep apnea (OSA) risk, restless legs syndrome (RLS) symptoms, and short sleep (SS). Factors associated with these sleep problems were also identified.
ARTHRITIS CARE & RESEARCH
(2023)
Article
Rheumatology
Laure Gossec, Stefan Siebert, Paul Bergmans, Kurt de Vlam, Elisa Gremese, Beatriz Joven-Ibanez, Tatiana Korotaeva, Frederic Lavie, Wim Noel, Michael T. Nurmohamed, Petros P. Sfikakis, Mohamed Sharaf, Elke Theander, Josef S. Smolen
Summary: This study evaluated the real-world persistence and effectiveness of the IL-12/23 inhibitor ustekinumab or a tumour necrosis factor inhibitor (TNFi) for psoriatic arthritis over 3 years. The results showed that the proportion of patients still on their initial treatments after 3 years was similar with ustekinumab and TNFi, but ustekinumab had a lower rate of adverse events.
ANNALS OF THE RHEUMATIC DISEASES
(2023)
Editorial Material
Rheumatology
Laura Coates, Laure Gossec
Article
Rheumatology
Jessica A. Walsh, Alexis Ogdie, Kaleb Michaud, Steven Peterson, Elizabeth A. Holdsworth, Chetan S. Karyekar, Nicola Booth, Chloe Middleton-Dalby, Soumya D. Chakravarty, Natalie Dennis, Laure Gossec
Summary: This study found that key manifestations of psoriatic arthritis (PsA) have varying impacts on quality of life, physical function, and work disability. These manifestations include peripheral arthritis, psoriasis, axial involvement, enthesitis, and dactylitis. The results show that these symptoms are associated with poorer general and disease-specific quality of life, physical function, and work disability.
Article
Rheumatology
Arno W. R. Van Kuijk, Mike T. Nurmohamed, Stefan Siebert, Paul Bergmans, Kurt de Vlam, Elisa Gremese, Beatriz Joven-Ibanez, T. Korotaeva, Frederic Lavie, Mohamed Sharaf, Wim Noel, Elke Theander, Josef S. Smolen, Laure Gossec, Irene E. van der Horst-bruinsma
Summary: The study found that female PsA patients had more severe disease characteristics before starting bDMARD treatment compared to males, with less improvement and lower treatment persistence. Further understanding of these differences may help improve therapeutic management in female PsA patients.
Article
Rheumatology
Paras Karmacharya, Courtney Stull, Alisa Stephens-Shields, M. Elaine Husni, Jose U. Scher, Ethan Craig, Robert Fitzsimmons, Soumya M. Reddy, Marina N. Magrey, Alexis Ogdie, Jessica A. Walsh
Summary: This study aimed to determine the responsiveness to therapy and minimum clinically important improvement (MCII) for patient-reported outcome measures in psoriatic arthritis (PsA) and to examine the impact of baseline disease activity on the ability to demonstrate change. Results showed that the standardized response means (SRMs) and MCII were relatively small in this real-world population, particularly among those with lower disease activity at baseline. BASDAI, cDAPSA, and PsAID12 were found to have good sensitivity to change, but selection for use in trials should consider the baseline disease activity of patients to be enrolled.
ARTHRITIS CARE & RESEARCH
(2023)
Article
Rheumatology
Gulsen Ozen, Sofia Pedro, Kaleb Michaud
Summary: A study comparing opioids and NSAIDs in patients with rheumatoid arthritis found that opioids had similar MACE risk but higher rates of all-cause mortality and VTE, suggesting that opioids are not safer than NSAIDs.
ANNALS OF THE RHEUMATIC DISEASES
(2023)
Article
Rheumatology
Philip J. Mease, Alice B. Gottlieb, Alexis Ogdie, Iain B. McInnes, Soumya D. Chakravarty, Emmanouil Rampakakis, Alexa Kollmeier, Xie L. Xu, May Shawi, Frederic Lavie, Mitsumasa Kishimoto, Proton Rahman
Summary: In guselkumab-treated patients with active PsA, earlier improvement in joint symptoms is significantly associated with lower RP rates through 2 years, indicating that blocking the IL-23 pathway may modify long-term disease course and prevent further joint damage.
CLINICAL RHEUMATOLOGY
(2023)
